# US 10,869,903 B2 · Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,869,903 B2
- Document ID: US10869903B2
- Status: Granted
- Kind: B2
- Application number: 15/495,522
- Filed: 2017-04-24
- Published: 2018-03-15
- Granted: 2020-12-22
- Earliest claimed: 2014-11-25
- Assignees: Evelo Biosciences, Inc.
- Applicants: Evelo Biosciences, Inc.
- Inventors: David Berry; Noubar B. Afeyan; Johanne Kaplan; Neal Gordon; Shaila Rahman
- Web page: https://patentgrep.com/patent/US10869903B2

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 9/0031: {Rectum, anus}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/7004: Monosaccharides having only carbon, hydrogen and oxygen atoms
- A61K 31/7016: Disaccharides, e.g. lactose, lactulose (lactobionic acid A61K31/7032)
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 35/39: Pancreas; Islets of Langerhans (Langerhans cells of epidermis A61K35/36)
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K 35/745: Bifidobacteria
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 38/46: Hydrolases (3)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2035/115: {Probiotics}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial or fungal entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent transplant disorders, e.g., graft-versus-host disease (GVHD), in a subject are also provided.

## Claims

### Claim 1

A method of reducing inflammation in the gastrointestinal tract of a subject, comprising orally administering to the subject a composition comprising an isolated population of bacteria of the genus Blautia, such that inflammation in the gastrointestinal tract of the subject is reduced.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition comprises an isolated population of bacteria selected from the group consisting of Blautia (Ruminococcus) coccoides, Blautia faecis, Blautia glucerasea, Blautia (Ruminococcus) hansenii, Blautia hydrogenotrophica (Ruminococcus hydrogenotrophicus), Blautia (Ruminococcus) luti, Blautia (Ruminococcus) obeum, Blautia producta (Ruminococcus productus), Blautia (Ruminococcus) schinkii, Blautia stercoris, Blautia uncultured bacterium clone BKLE_a03_2 (GenBank: EU469501.1), Blautia uncultured bacterium clone SJTU_B_14_30 (GenBank: EF402926.1), Blautia uncultured bacterium clone SJTU_C_14_16 (GenBank: EF404657.1), Blautia uncultured bacterium clone S1-5 (GenBank: GQ898099.1), Blautia uncultured PAC000178_s, Blautia wexlerae, and combinations thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition comprises an isolated population of bacteria from the species Blautia hydrogenotrophica.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition contains a single species of bacteria.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition does not comprise bacterial cells of the species Blautia producta.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition comprises an isolated population of bacteria from the species Blautia stercoris.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition comprises an isolated population of bacteria from the species Blautia wexlerae.